GL1X · GenesisL1 explorer

Research workbench

Identification of novel P38 alpha MAP kinase inhibitors using fragment-based lead generation.

Analyse Identification of novel P38 alpha MAP kinase inhibitors using fragment-based… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
1WBS
Type
protein
Length
351 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Mitogen-activated protein kinase 14
EC
2.7.1.37
UniProt
Q16539
Ligands
LI2
Pockets
4 · best druggability 0.79

Structure

x-ray diffraction · 1 distinct chain · 39% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMitogen-activated protein kinase 14 (EC 2.7.1.37)protein35139% helix, 15% strandQ16539

Ligands and binding sites

  • LI2 · 3-fluoro-5-morpholin-4-yl-N-[3-(2-pyridin-4-ylethyl)-1H-indol-5-yl]benzamide · ligand · chains A
  • GOL · Glycerol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17150.790.8372LI2
21400.450.7619empty
31030.400.7629empty
4570.280.7415empty

Compared structures

  • 1WBS · Identification of novel p38 alpha MAP Kinase inhibitors using fragment-based lead… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.